百岁新生血管性年龄相关性黄斑变性患者的临床特征
结果显示,长期抗VEGF治疗下57%的眼最佳矫正视力稳定或改善,末次平均BCVA为53个字母(21.8),Snellen等效20/100;基线BCVA更高(P<0.001)和中心凹下脉络膜更厚(P=0.03)与更好视力结局相关,黄斑出血(25%)和黄斑萎缩(53.6%)与更差BCVA相关。
要点
- 百岁nAMD患者长期抗VEGF治疗下57%的眼BCVA稳定或改善。
- 末次平均BCVA为53个字母(21.8),Snellen等效20/100。
- 基线BCVA更高和中心凹下脉络膜更厚与更好视力结局相关。
核心结论
- 百岁nAMD患者可通过长期抗VEGF治疗维持视力,需针对其挑战制定个体化管理策略。
研究设计与样本
- 回顾性纵向研究,在两家欧洲视网膜转诊中心开展,纳入末次随访时年龄≥100岁的nAMD患者。
主要发现
- 多数眼(86%)表现为1型黄斑新生血管。
- 末次随访时57%的眼BCVA稳定或改善,平均最终BCVA为53个字母(21.8),Snellen等效20/100。
- BCVA>50字母的眼基线BCVA显著更高(P<0.001)且中心凹下脉络膜厚度更厚(P=0.03)。
- 黄斑出血(25%)和黄斑萎缩(53.6%)与更差BCVA相关。
关键数值与推荐
- 视力结局较好(BCVA>50字母)与基线BCVA更高(P<0.001)及中心凹下脉络膜厚度更厚(P=0.03)相关。
- 黄斑出血占25%、黄斑萎缩占53.6%,均与更差BCVA相关。
临床怎么用
- 对百岁nAMD患者可考虑长期抗VEGF治疗以维持视力。
- 关注基线BCVA、中心凹下脉络膜厚度、黄斑出血和黄斑萎缩等预后相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report clinical characteristics of exudative neovascular age-related macular degeneration in centenarian patients. METHODS: A retrospective, longitudinal study conducted in two retinal referral centers in Europe. Clinical characteristics of patients with neovascular age-related macular degeneration having at last follow-up at least 100 years and older were reviewed. RESULTS: Twenty-eight eyes from 14 patients (13 women), with a mean baseline age of 95.7 (SD 4.1) years and a mean follow-up duration of 89 months (39.9). The mean age at the last follow-up was 102.4 (1.7) years. Most eyes (86%) presented Type 1 macular neovascularization. At the last follow-up, best-corrected visual acuity was stable or improved in 57% of eyes, with a mean final best-corrected visual acuity of 53 letters (21.8), Snellen equivalent 20/100. Eyes with better visual outcomes (>50 letters) had significantly higher baseline best-corrected visual acuity ( P < 0.001) and thicker subfoveal choroidal thickness ( P = 0.03). Macular hemorrhage (25%) and macular atrophy (53.6%) were associated with poorer best-corrected visual acuity. CONCLUSION: Centenarian patients with neovascular age-related macular degeneration can maintain vision with long-term anti-VEGF therapy. These findings underscore the need for tailored management strategies for the challenges faced by centenarians with neovascular age-related macular degeneration.
引用
- Capuano V, Fragiotta S, Abadou J, et al. CENTENARIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2026. PMID: 41879644. doi:10.1097/IAE.0000000000004837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。